Version 1
: Received: 25 April 2024 / Approved: 26 April 2024 / Online: 28 April 2024 (08:09:01 CEST)
How to cite:
Sugiura, T.; Shahannaz, D.C.; Ferrell, B.E. Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. Preprints2024, 2024041796. https://doi.org/10.20944/preprints202404.1796.v1
Sugiura, T.; Shahannaz, D.C.; Ferrell, B.E. Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. Preprints 2024, 2024041796. https://doi.org/10.20944/preprints202404.1796.v1
Sugiura, T.; Shahannaz, D.C.; Ferrell, B.E. Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. Preprints2024, 2024041796. https://doi.org/10.20944/preprints202404.1796.v1
APA Style
Sugiura, T., Shahannaz, D.C., & Ferrell, B.E. (2024). Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells. Preprints. https://doi.org/10.20944/preprints202404.1796.v1
Chicago/Turabian Style
Sugiura, T., Dhienda C Shahannaz and Brandon E Ferrell. 2024 "Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells" Preprints. https://doi.org/10.20944/preprints202404.1796.v1
Abstract
Heart failure (HF) is a life-threatening disorder and is treated by drug therapies and surgical interventions such as heart transplantation and left ventricular assist device (LVAD). However, these treatments can lack effectiveness in the long term and are associated with issues such as donor shortage in heart transplantation, and infection, stroke, or gastrointestinal bleeding in LVADs. Therefore, alternative therapeutic strategies are still needed. In this respect, stem cell therapy has been introduced for the treatment of HF and numerous preclinical and clinical studies using various types of stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have been shown to improve cardiac function and attenuate left ventricular remodeling. IPSCs, which have a capacity of unlimited proliferation and differentiation to cardiomyocytes, are a promising cell source for myocardial regeneration therapy. This review discusses the current status of cardiac regenerative therapy using iPSCs.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
